Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Biomed Mater Eng ; 34(4): 289-304, 2023.
Article in English | MEDLINE | ID: mdl-36617774

ABSTRACT

BACKGROUND: Fibrous capsules (Fb) in response to cardiovascular implantable electronic devices (CIEDs), including a pacemaker (P) system, can produce patient discomfort and difficulties in revision surgery due partially to their increased compressive strength, previously linked to elevated tissue fibers. OBJECTIVE: A preliminary study to quantify structural proteins, determine if biologic extracellular matrix-enveloped CIEDs (PECM) caused differential Fb properties, and to implement a realistic mechanical model. METHODS: Retrieved Fb (-P and -PECM) from minipigs were subjected to biomechanical (shear oscillation and uniaxial compression) and histological (collagen I and elastin) analyses. RESULTS: Fb-PECM showed significant decreases compared to Fb-P in: low strain-loss modulus (390 vs. 541 Pa) across angular frequencies, high strain-compressive elastic modulus (1043 vs. 2042 kPa), and elastic fiber content (1.92 vs. 3.15 µg/mg tissue). Decreases in elastin were particularly noted closer to the implant's surface (Fb-PECM = 71% vs. Fb-P = 143% relative to dermal elastin at mid-tangential sections) and verified with a solid mechanics hyperelasticity with direction-dependent fiber viscoelasticity compression simulation (r2 ≥ 98.9%). CONCLUSIONS: The biologic envelope composed of decellularized porcine small intestine submucosa ECM for CIEDs promoted fibrous tissues with less elastic fibers. Novel compression modeling analyses directly correlated this singular reduction to more desirable subcutaneous tissue mechanics.


Subject(s)
Biological Products , Elastin , Swine , Animals , Elastin/analysis , Elastin/metabolism , Swine, Miniature/metabolism , Elastic Tissue/metabolism , Extracellular Matrix/chemistry , Elastic Modulus/physiology , Biological Products/analysis , Biological Products/metabolism , Biomechanical Phenomena
2.
J Mech Behav Biomed Mater ; 55: 87-103, 2015 Mar.
Article in English | MEDLINE | ID: mdl-26569044

ABSTRACT

Tissue engineering and cell based liver therapies have utilized primary hepatocytes with limited success due to the failure of hepatocytes to maintain their phenotype in vitro. In order to overcome this challenge, hyaluronic acid (HA) cell culture substrates were formulated to closely mimic the composition and stiffness of the normal liver cellular microenvironment. The stiffness of the substrate was modulated by adjusting HA hydrogel crosslinking. Additionally, the repertoire of bioactive molecules within the HA substrate was bolstered by supplementation with normal liver extracellular matrix (ECM). Primary human hepatocyte viability and phenotype were determined over a narrow physiologically relevant range of substrate stiffnesses from 600 to 4600Pa in both the presence and absence of liver ECM. Cell attachment, viability, and organization of the actin cytoskeleton improved with increased stiffness up to 4600Pa. These differences were not evident in earlier time points or substrates containing only HA. However, gene expression for the hepatocyte markers hepatocyte nuclear factor 4 alpha (HNF4α) and albumin significantly decreased on the 4600Pa stiffness at day 7 indicating that cells may not have maintained their phenotype long-term at this stiffness. Function, as measured by albumin secretion, varied with both stiffness and time in culture and peaked at day 7 at the 1200Pa stiffness, slightly below the stiffness of normal liver ECM at 3000Pa. Overall, gel stiffness affected primary human hepatocyte cell adhesion, functional marker expression, and morphological characteristics dependent on both the presence of liver ECM in gel substrates and time in culture.


Subject(s)
Extracellular Matrix/metabolism , Hepatocytes/cytology , Hyaluronic Acid/chemistry , Hyaluronic Acid/pharmacology , Liver/cytology , Mechanical Phenomena , Tissue Engineering , Animals , Biocompatible Materials/chemistry , Biocompatible Materials/pharmacology , Biomarkers/metabolism , Cell Adhesion/drug effects , Cell Survival/drug effects , Cell Transplantation , Cytoplasm/drug effects , Cytoplasm/enzymology , Gene Expression Regulation/drug effects , Glycosaminoglycans/metabolism , Hepatocytes/drug effects , Hepatocytes/metabolism , Humans , Hydrogels/chemistry , Protein Kinases/metabolism , Rats , Solubility , rho GTP-Binding Proteins/metabolism
3.
Biomaterials ; 40: 72-9, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25433603

ABSTRACT

Donor shortage remains a continued challenge in liver transplantation. Recent advances in tissue engineering have provided the possibility of creating functional liver tissues as an alternative to donor organ transplantation. Small bioengineered liver constructs have been developed, however a major challenge in achieving functional bioengineered liver in vivo is the establishment of a functional vasculature within the scaffolds. Our overall goal is to bioengineer intact livers, suitable for transplantation, using acellular porcine liver scaffolds. We developed an effective method for reestablishing the vascular network within decellularized liver scaffolds by conjugating anti-endothelial cell antibodies to maximize coverage of the vessel walls with endothelial cells. This procedure resulted in uniform endothelial attachment throughout the liver vasculature extending to the capillary bed of the liver scaffold and greatly reduced platelet adhesion upon blood perfusion in vitro. The re-endothelialized livers, when transplanted to recipient pigs, were able to withstand physiological blood flow and maintained for up to 24 h. This study demonstrates, for the first time, that vascularized bioengineered livers, of clinically relevant size, can be transplanted and maintained in vivo, and represents the first step towards generating engineered livers for transplantation to patients with end-stage liver failure.


Subject(s)
Bioengineering , Endothelium, Vascular/physiology , Liver Transplantation , Liver/blood supply , Liver/physiology , Animals , Female , Liver/ultrastructure , Prosthesis Implantation , Sus scrofa , Tissue Scaffolds , Vascular Patency
4.
Biomaterials ; 33(31): 7756-64, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22841923

ABSTRACT

End-stage renal failure is a devastating disease, with donor organ transplantation as the only functional restorative treatment. The current number of donor organs meets less than one-fifth of demand, so regenerative medicine approaches have been proposed as potential therapeutic alternatives. One such approach for whole large-organ bioengineering is to combine functional renal cells with a decellularized porcine kidney scaffold. The efficacy of cellular removal and biocompatibility of the preserved porcine matrices, as well as scaffold reproducibility, are critical to the success of this approach. We evaluated the effectiveness of 0.25 and 0.5% sodium dodecyl sulfate (SDS) and 1% Triton X-100 in the decellularization of adult porcine kidneys. To perform the decellularization, a high-throughput system was designed and constructed. In this study all three methods examined showed significant cellular removal, but 0.5% SDS was the most effective detergent (<50 ng DNA/mg dry tissue). Decellularized organs retained intact microarchitecture including the renal vasculature and essential extracellular matrix components. The SDS-treated decellularized scaffolds were non-cytotoxic to primary human renal cells. This method ensures clearance of porcine cellular material (which directly impacts immunoreactivity during transplantation) and preserves the extracellular matrix and cellular compatibility of these renal scaffolds. Thus, we have developed a rapid decellularization method that can be scaled up for use in other large organs, and this represents a step toward development of a transplantable organ using tissue engineering techniques.


Subject(s)
High-Throughput Screening Assays/methods , Kidney/physiology , Tissue Engineering/methods , Animals , Cell Death/drug effects , Cells, Cultured , Detergents/pharmacology , Extracellular Matrix/drug effects , Extracellular Matrix/metabolism , Humans , Kidney/blood supply , Kidney/drug effects , Perfusion , Sus scrofa , Tissue Scaffolds/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...